Published in J Clin Oncol on April 18, 2011
The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. Urology (2014) 2.02
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2014) 1.81
Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol (2012) 1.56
Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity. BJU Int (2014) 1.55
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Can Urol Assoc J (2016) 1.08
Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift? J Clin Oncol (2011) 1.02
Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Int J Clin Oncol (2012) 1.02
Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol (2012) 1.01
Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. Clin Genitourin Cancer (2012) 0.98
Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Ther Adv Urol (2015) 0.98
Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer (2014) 0.95
Targeted therapies in bladder cancer: an overview of in vivo research. Nat Rev Urol (2015) 0.94
Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. Can Urol Assoc J (2013) 0.94
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol Oncol (2015) 0.91
Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther (2011) 0.90
Progress in personalizing chemotherapy for bladder cancer. Adv Urol (2012) 0.89
Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. J Magn Reson Imaging (2014) 0.89
Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. Can Urol Assoc J (2014) 0.87
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol (2012) 0.87
Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review. World J Urol (2012) 0.86
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw (2016) 0.85
Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time. Can Urol Assoc J (2015) 0.84
Bladder cancer in 2011: the dawn of personalized medicine. Nat Rev Urol (2011) 0.84
Upper urinary tract disease: what we know today and unmet needs. Transl Androl Urol (2015) 0.83
ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer (2012) 0.83
Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv Urol (2014) 0.83
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist (2016) 0.83
A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett (2012) 0.83
Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clin Genitourin Cancer (2014) 0.82
Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer. Oncologist (2013) 0.82
Adjuvant chemotherapy is associated with decreased mortality after radical cystectomy for locally advanced bladder cancer. World J Urol (2014) 0.82
Systemic therapy for bladder cancer - a medical oncologist's perspective. J Solid Tumors (2014) 0.82
Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. BMC Urol (2015) 0.81
Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer (2014) 0.81
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol (2016) 0.81
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol (2014) 0.80
Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Adv Urol (2013) 0.80
Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider? Transl Androl Urol (2016) 0.79
Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation. Mol Clin Oncol (2014) 0.79
Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clin Genitourin Cancer (2015) 0.79
Optimal management of muscle-invasive bladder cancer - a review. Res Rep Urol (2015) 0.79
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer (2016) 0.79
Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer. Bladder Cancer (2016) 0.78
Urothelial carcinoma management in elderly or unfit patients. EJC Suppl (2016) 0.78
Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy. Virchows Arch (2012) 0.78
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. Br J Cancer (2015) 0.78
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. World J Urol (2015) 0.78
Circulating Biomarkers in Bladder Cancer. Bladder Cancer (2016) 0.77
Bladder Preservation for Muscle Invasive Bladder Cancer. Bladder Cancer (2016) 0.77
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers. Curr Treat Options Oncol (2016) 0.77
Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World J Urol (2013) 0.77
Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. Bladder Cancer (2016) 0.77
Contemporary management of muscle-invasive bladder cancer. Expert Rev Anticancer Ther (2012) 0.77
Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Transl Androl Urol (2015) 0.77
The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. World J Urol (2013) 0.77
Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Can Urol Assoc J (2016) 0.77
The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. Int J Clin Oncol (2016) 0.76
Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Rev Anticancer Ther (2012) 0.76
CKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer. PLoS One (2014) 0.76
Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (concomitant boost), with or without concurrent cisplatin, for patients with invasive bladder cancer - clinical outcome. Contemp Oncol (Pozn) (2013) 0.76
High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer. BMC Cancer (2014) 0.76
Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery. Int J Clin Oncol (2015) 0.76
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer (2016) 0.76
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. BMC Cancer (2016) 0.75
Autophagy and urothelial carcinoma of the bladder: A review. Investig Clin Urol (2016) 0.75
A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncol (2016) 0.75
Building bridges in urothelial carcinoma to face common challenges. Transl Androl Urol (2016) 0.75
Systemic therapy for bladder cancer finally comes into a new age. Future Oncol (2016) 0.75
Systemic Therapy for Invasive Bladder Cancer: The Value Proposition. Oncologist (2016) 0.75
Bladder cancer: Time to embrace neoadjuvant chemotherapy for invasive disease. Nat Rev Urol (2011) 0.75
Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. Eur Urol (2012) 0.75
Systemic therapy in bladder cancer. Indian J Urol (2017) 0.75
Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract. Br J Cancer (2014) 0.75
A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. PLoS One (2017) 0.75
Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. J Clin Oncol (2016) 0.75
National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol (2016) 0.75
Update on the management of invasive bladder cancer 2012. Cancer Manag Res (2012) 0.75
Invasive bladder cancer: ignoring the data. Oncologist (2013) 0.75
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). Clin Transl Oncol (2016) 0.75
Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma. Clin Genitourin Cancer (2015) 0.75
Optimizing care and outcomes of patients with muscle-invasive bladder cancer. Can Urol Assoc J (2014) 0.75
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. Can Urol Assoc J (2014) 0.75
Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. Curr Opin Oncol (2012) 0.75
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol (2016) 0.75
Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study. Bladder Cancer (2017) 0.75
Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery? Urol Clin North Am (2015) 0.75
Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study. PLoS One (2017) 0.75
The Role of Population-Based Observational Research in Bladder Cancer. Bladder Cancer (2015) 0.75
New discoveries in the molecular landscape of bladder cancer. F1000Res (2016) 0.75
The Rationale for Post-Operative Radiation in Localized Bladder Cancer. Bladder Cancer (2017) 0.75
Prediction of cancer cell sensitivity to natural products based on genomic and chemical properties. PeerJ (2015) 0.75
[Prediction of local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. A novel risk stratification]. Strahlenther Onkol (2013) 0.75
Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing. Transl Androl Urol (2016) 0.75
Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol (2016) 0.75
Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. Sci Rep (2017) 0.75
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol (2005) 4.57
The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol (2009) 2.92
Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol (2005) 2.58
Volume, process of care, and operative mortality for cystectomy for bladder cancer. Urology (2007) 2.07
The changing pattern of mortality and morbidity from radical cystectomy. BJU Int (2000) 1.68
Current chemotherapeutic options for the treatment of advanced bladder cancer: a review. Urol Oncol (2010) 1.43
Advanced bladder cancer: new agents and new approaches. A review. Urol Oncol (2010) 1.28
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. J Cell Biol (2008) 9.37
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2010) 7.70
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol (2012) 7.16
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet (2006) 6.67
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med (2002) 6.10
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (2011) 5.76
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2008) 5.56
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol (2004) 5.38
HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med (2006) 5.10
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol (2007) 5.00
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet (2007) 4.68
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet (2009) 4.58
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol (2011) 4.25
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol (2014) 3.90
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (2010) 3.78
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol (2013) 3.40
Disruption of Toxoplasma gondii parasitophorous vacuoles by the mouse p47-resistance GTPases. PLoS Pathog (2005) 3.25
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol (2013) 3.11
Selected lipids activate phagosome actin assembly and maturation resulting in killing of pathogenic mycobacteria. Nat Cell Biol (2003) 2.99
Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol (2002) 2.98
European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol (2013) 2.93
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst (2007) 2.86
A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2006) 2.80
Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol (2013) 2.78
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet (2008) 2.77
European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol (2011) 2.70
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst (2003) 2.68
Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J Bacteriol (2008) 2.60
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol (2008) 2.57
Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol (2008) 2.55
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 2.42
Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.26
Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots. J Natl Cancer Inst (2008) 2.26
Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med (2003) 2.21
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol (2008) 2.20
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol (2009) 2.18
Dia1 and IQGAP1 interact in cell migration and phagocytic cup formation. J Cell Biol (2007) 2.15
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer (2006) 2.14
American society of clinical oncology policy statement: disparities in cancer care. J Clin Oncol (2009) 2.12
RanGTP mediates nuclear pore complex assembly. Nature (2003) 2.08
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol (2012) 2.06
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med (2011) 1.92
Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials. Clin Trials (2004) 1.85
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials (2009) 1.81
Evaluation of the antimicrobial activities of plant oxylipins supports their involvement in defense against pathogens. Plant Physiol (2005) 1.80
Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit Care Med (2005) 1.77
Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome. Cell Microbiol (2010) 1.77
Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer (2010) 1.77
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer (2008) 1.73
Filopodia act as phagocytic tentacles and pull with discrete steps and a load-dependent velocity. Proc Natl Acad Sci U S A (2007) 1.72
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
A role for the small GTPase Rab21 in the early endocytic pathway. J Cell Sci (2004) 1.57
Phagocytosis: latex leads the way. Curr Opin Cell Biol (2003) 1.54
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53
Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. Clin Trials (2004) 1.53
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol (2013) 1.50
Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol (2008) 1.50
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract (2013) 1.48
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials (2012) 1.48
Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors? Eur Urol (2010) 1.47
Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol (2013) 1.45
Prostate cancer: what did we learn from the 2012 Annual Scientific Meeting of ASCO? Oncology (Williston Park) (2012) 1.43
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. J Clin Oncol (2005) 1.40
Fusion between phagosomes, early and late endosomes: a role for actin in fusion between late, but not early endocytic organelles. Mol Biol Cell (2003) 1.36
Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med (2004) 1.36
Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial. J Urban Health (2013) 1.34
Severe periodontitis is associated with systemic inflammation and a dysmetabolic status: a case-control study. J Clin Periodontol (2007) 1.32
Integrated network reconstruction, visualization and analysis using YANAsquare. BMC Bioinformatics (2007) 1.32